نم	*	JC03 R	ec'd PCT/PTO 31 MAR 2005 PC+			
	First Class Mail		PTO/SB/21 (09-04)			
	S desired A	U.S. no persons are required to respond to a c	Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trade Office; U.S. DEPARTMENT OF COMMERCE			
Under the Pa	perwork Reduction Act 25	Application Number	. 10/510,585			
ALP AN	ANSMITTAL	Filing Date	8 October 2004			
FORM		First Named Inventor	Debra FLEENOR et al.			
MAR 3 1 200	(S) _	Art Unit	·			
	all prespondence after initial	Examiner Name	·			
Jotal Number ø	ages in This Submission	6 Attorney Docket Number	2354 US F			
RADE		ENCLOSURES (Check a	II that apply)			
			After Allowance Communication to TC			
Fee Tran	smittal Form	Drawing(s)	Appeal Communication to Board			
LJ F	ee Attached	Licensing-related Papers	of Appeals and Interferences			
Amendm	ent/Reply	Petition	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)			
	After Final	Petition to Convert to a Provisional Application	Proprietary Information			
		Power of Attorney, Revocat	ion Status Letter			
Affidavits/declaration(s) Extension of Time Request		Change of Correspondence	Other Enclosure(s) (please Identify			
		Terminal Disclaimer	below):			
Express	Abandonment Request	Request for Refund	corresponding EP 03718502.2			
≭ Informati	on Disclosure Statement	CD, Number of CD(s)	European Search Report [3 pp] and			
		Landscape Table on 0	Return Card.			
Certified Docume	Copy of Priority nt(s)	Remarks				
	Missing Parts/ ete Application					
F	Reply to Missing Parts					
\	ınder 37 CFR 1.52 or 1.53					
	SIGNA	TURE OF APPLICANT, ATT	OPNEY OR AGENT			
Firm Name	SIGNA	TORE OF AFFEIGANT, ATT	ORNET, OR AGENT			
		Alcon Researc	ch, Ltd.			
Signature	Signature Olyma Wlull					
Printed name Teresa J. Schultz						
Date 28 Murun		arch 2005	Reg. No. 40,526			
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
	Signature Colon Melman					

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Barbara McKenzie

Typed or printed name

Date

28 March 2005

10 Rosy POWER

3 1 MAR 2005

IN THE USE TED STATES PATENT AND TRADE

MAR 3 1 2005

RK OFFICE

In re Application of: Debra ThankOR et al

Serial No: 10/510,585 Filed: 8 October 2004

Examiner:

Group Art Unit:

FOR: Agents Which Regulate, Inhibit, Or Modulate The Activity And/Or Expression Of

Connective Tissue Growth Factor (CTGF) As A Unique Means To Both Lower Intraocular Pressure And Treat Glaucomatous Retinopathies/Optic Neuropathies

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit a copy of the corresponding European Search Report issued in the EP application is included for the Examiner's convenience. The references are listed on the attached PTO Form 1449.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

Date

Teresa J. Schultz

Registration No. 40,256

817-551-4231

Address for Correspondence:
Alcon Research, Ltd.
Attn: Teresa J. Schultz
6201 S. Freeway, Mail Code Q-148
Fort Worth, TX 76134-2099

Attorney Docket No.: 2354 US F

PTO/SB/08A (08-03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduc ons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/510,585				
Filing Date	8 October 2004 Debra FLEENOR et al.				
First Named Inventor					
Art Unit					
Examiner Name					
Attorney Docket Number	2354 US F				

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# know}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6,316,465	11/13/2001	Pershadingh et al.	
		US-			

		FOREIGN	I PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
		WO 00/30628 A2	06/02/2000	Genetech, Inc.		
		WO 01/25226 A1	04/12/2001	Bethesda Pharm.		
		WO 02/13812 A1	02/21/2002	Pershadsingh		
		WO 03/049773 A1	06/19/03	Fibrogen, Inc.		
	<u> </u>					otacluster

Examiner	Date	
Signature	Considered	
•		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not applicant. Applicant's unique citation designation number (optional). See Kinds Codes of the form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of the form with next communication to applicant. For the form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of the form with next communication to applicant. considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.